The Alzheimer's Drug Discovery Foundation (ADDF) has
been a source of several peer-reviewed grants supporting PTX technology and its
peer-reviewed Biotechnology Program maintains scientific oversight and an equity
position in PTX.
In 2016 PharmatrophiX was awarded a peer-reviewed NIH/National Institute of Aging Alzheimer’s Disease Pilot Clinical Trial Award to provide support for its current phase 2a exploratory endpoint trial. In 2018, additional funding was provided to expand subject enrollment and testing. The principal investigator is Dr. Manfred Windisch, CEO and President, NeuroScios, a PharmatrophiX partner and the co-investigator is Dr. Maria Eriksdotter at the Karolinska Institute in Stockholm.